Search results
CAR-T cell therapy to treat blood cancers unlikely to increase risk of secondary cancers
United Press International via Yahoo News· 6 days agoCAR-T cell therapy to treat blood cancers is safer than previously thought, with little risk that...
EU regulator mandates label updates on CAR-T cancer therapies
Reuters via AOL· 5 days agoThe European Medicines Agency's (EMA) mandate, which echoes the one issued by the U.S. health...
Immunotherapy to treat cancer gave rise to 2nd cancer in extremely rare case
LiveScience· 6 days agoFor many people, the treatment has been life-changing — however, as the first CAR T-cell therapy was...
11-year-old cancer survivor thriving after treatment supported by Alex's Lemonade Stand
CBS News· 9 hours agoThe family of a child fighting pediatric cancer was out of options when a doctor proposed a...
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 2 days agoMB-106 is being developed in a collaboration...Fred Hutch Cancer Center to treat patients with...
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Zacks via Yahoo Finance· 17 hours agoUpdated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell ...
How Glowing Dye That Clings to Cancer Cells Gives Doctors ‘second pair of eyes’
GoodNewsNetwork· 5 days agoDeveloped for use in the removal of prostate cancer, the dye could be adapted to other cancers but...
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Digital Journal· 2 days agoOperations Update LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the...
NewMediaWire via Yahoo Finance· 20 hours ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen,...
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Earns Buy Rating from HC Wainwright
ETF DAILY NEWS· 2 days agoActinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Monday, Benzinga ...